Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
Tóm tắt
Busulfan is an alkylating agent that is widely used in preparative regimens for bone marrow transplantation (BMT). We developed a high-performance liquid chromatographic (HPLC) assay for the determination of plasma busulfan concentrations in 30 patients who received oral doses of 1 mg/kg. Concentrations were fit by a one-compartment pharmacokinetic model with first-order absorption. The pattern of absorption and elimination varied widely between patients, with peak concentrations ranging from 1.2 to 10.4 μmol/l (mean, 4.25±2.49). The climination half-life ranged from 58 to 433 min (harmonic mean, 140 min). The AUC contributed by a single oral dose ranged from 606 to 5,144 μmol-min/l (mean, 2,012±1,223). Patients were evaluated for the development of veno-occlusive disease (VOD), a treatment complication that occurs in 20% of patients undergoing BMT and causes 10% of transplantation-related deaths. All six patients who developed VOD had an AUC greater than the mean, and five of them had an AUC that was >1 SD above the mean. The occurrence of VOD was highly correlated with an increased AUC (>1 SD above the mean) (X2=18;P<0.0001). Using multivariate logistic regression, no other statistically significant pharmacokinetic predictor of VOD was found. The tenfold variability in the busulfan AUC and the statistical association of increased AUC with the development of VOD suggest a possible role for therapeutic monitoring in this setting.
Tài liệu tham khảo
Berk PO, Popper H, Krueger GRF, Decter J, Herzig G, Graw RG (1979) Veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Possible association with graftversus-host disease. Ann Intern Med 90: 158
Beschorner WE, Pino J, Boitnott JK, Tutschka PJ, Santos GW (1980) Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection. Am J Pathol 99: 369
Bishop JB, Wassom JS (1986) Toxicologic review of busulfan (Myleran). Mutat Res 168: 15
Canellos GP (1977) The treatment of chronic granulocytic leukemia. Clin Haematol 6: 113
Ehrsson H, Hassan M (1984) Binding of busulfan to plasma proteins and blood cells. J Pharm Pharmacol 36: 694
Ehrsson H, Hassan M, Ehrnebo M, Beran M (1983) Busulfan kinetics. Clin Pharmacol Ther 34: 86
Gibaldi M, Perrier D (eds) (1982) Pharmacokinetics. Marcel Dekker, New York, p 132
Hassan M, Ehrsson J (1987) Urinary metabolites of busulfan in the rat. Drug Metab Dispos 15: 399
Hasson M, Ehrsson H (1987) Metabolism of*14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 12: 71
Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S (1977) Disposition of aminopyrine, antipyrine diazepam and indocyanine green in patients with liver disease or on anticonvulsant therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med 90: 440
Hudson RF, Timmis GM, Marshall RD (1958) A physicochemical investigation into the biological action of Myleran and related sulphonic acid esters. Biochem Pharmacol 1: 48
Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R (1987) Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 44: 778
Kader AT, Stirling CJM (1962) Elimination-addition: I. Displacement of sulphonyl groups from diarylsulphonylalkanes. J Chem Soc 3: 3686
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4: 116
McDonald GB, Sharma P, Matthews DE, Schulman HM, Thomas ED (1985) The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation. Transplantation 39: 603
Nadkarni MV, Trams EG, Smith PK (1959) Preliminary studies on the distribution and fate of TEM, TEPA and myleran in the human. Cancer Res 19: 713
Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, Bast RC Jr, Seigler HF, Colvin OM (1987) Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47: 6402
Roberts JJ, Warwick GP (1961) The mode of action of alkylating agents: III. The formation of 3-hydroxytetra-hydrothiophene-1∶1-dioxide from 1∶4-dimethane sulphonyloxybutane (Myleran),S-B-alanyl-tetrahydrothiophenium mesylate, tetrahydrothiophene-1∶1 dioxide in the rat, rabbit and mouse. Biochem Pharmacol 6: 217
Rollins BJ (1986) Hepatic veno-occlusive disease. Am J Med 81: 297
Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM (1983) Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 309: 1347
Trams EG, Nadkarni MV, de Quattro V, Maengwyn-Davies GD, Smith PK (1959) Dimethane sulphonoxybutane (myleran): preliminary studies and metabolic fate in the rat. Biochem Pharmacol 2: 7
Vodopick H, Hamilton HE, Jackson HL, Peng CT, Sheets RF (1969) Metabolic fate of busulfan in man. J Lab Clin Med 73: 266